NASDAQ · CUE
Healthcare · Biotechnology
$31.64
Up+$2.31 (+7.29%)
Updated Sep 16, 2026, 5:22 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CUE closed at $31.64 after 20 trading sessions, up 23.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $30.65 | $32.00 | $29.26 | $31.64 | 127.17K |
| Sep 14, 2026 | $28.24 | $31.10 | $28.24 | $30.55 | 136.6K |
| Sep 11, 2026 | $28.38 | $28.89 | $27.50 | $28.74 | 122.77K |
| Sep 10, 2026 | $30.20 | $30.905 | $27.50 | $28.00 | 143.19K |
| Sep 9, 2026 | $30.00 | $32.13 | $30.00 | $30.50 | 174.15K |
| Sep 8, 2026 | $27.39 | $30.24 | $25.62 | $30.00 | 260.04K |
| Sep 4, 2026 | $27.55 | $27.95 | $27.025 | $27.44 | 50.42K |
| Sep 3, 2026 | $26.60 | $28.09 | $26.60 | $27.67 | 65.68K |
| Sep 2, 2026 | $28.32 | $28.93 | $25.04 | $26.96 | 127.87K |
| Sep 1, 2026 | $25.29 | $29.28 | $25.01 | $28.44 | 177.42K |
| Aug 31, 2026 | $27.48 | $28.9749 | $25.075 | $25.52 | 101.12K |
| Aug 28, 2026 | $28.64 | $29.75 | $26.8517 | $27.88 | 102.26K |
| Aug 27, 2026 | $28.85 | $29.20 | $26.38 | $28.16 | 225.52K |
| Aug 26, 2026 | $26.63 | $29.325 | $26.26 | $28.85 | 205.09K |
| Aug 25, 2026 | $23.69 | $28.29 | $23.405 | $26.76 | 170.47K |
| Aug 24, 2026 | $23.97 | $24.193 | $22.56 | $23.18 | 136.57K |
| Aug 21, 2026 | $25.55 | $26.00 | $23.235 | $23.98 | 177.75K |
| Aug 20, 2026 | $26.44 | $28.11 | $24.40 | $24.61 | 158.05K |
| Aug 19, 2026 | $26.46 | $27.20 | $25.17 | $26.28 | 166.44K |
| Aug 18, 2026 | $27.39 | $27.95 | $24.31 | $25.70 | 270.69K |
The latest Smart Investors Daily articles mentioning CUE.
CUE research
Company profile and research snapshot.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2025 | LUCID CAPITAL MARKETS | Buy | — |
| Apr 2, 2025 | Citizens Capital Markets | Market Outperform | — |
| Aug 20, 2024 | Stifel | Buy | — |
| Jul 26, 2024 | JMP Securities | Market Outperform | — |
| Jul 26, 2024 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst consensus estimate of $(1.69) by 1328.4 percent. This is a 794.07 percent decrease over losses of $(2.70) per share
Benzinga · Aug 12, 2026
https://www.sec.gov/Archives/edgar/data/1645460/000119312526346867/d136967ds3.htm
Benzinga · Aug 3, 2026
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial
SeekingAlpha · Jul 10, 2026
Cue Biopharma (CUE) stock analysis: overvaluation, cash runway risk, and likely dilution could triple shares.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CUE.
